Enerpac Tool Group Earnings Call Transcripts
Fiscal Year 2026
-
PROPEL targets 4%–6% organic growth and 10%–13% EPS CAGR through FY 2030, backed by commercial expansion, innovation and operational improvement. SFE adds scale and a $4M–$6M year-three adjusted EBITDA synergy target.
-
FY26 revenue hit a record $652 million and free cash flow rose 30%. SFE closed, and FY27 guidance calls for 4%-6% organic growth, with integration and growth investments underway.
-
Q3 saw solid product growth and sequential service improvement, offset by Middle East conflict headwinds. Announced SFE Group acquisition expands addressable market and is expected to be accretive to EPS in fiscal 2027. Guidance reflects margin impacts from service delays and business mix.
-
Second quarter fiscal 2026 delivered 2% organic revenue growth, with strong product sales offset by service declines, especially in EMEA. Guidance was narrowed, innovation accelerated, and a major UK contract was secured, while restructuring and capital returns continued.
-
Shareholders elected eight directors, approved the auditor for fiscal 2026, and supported executive compensation. Quorum was achieved with over 95% of shares represented, and no questions were raised during the meeting.
-
Q1 FY26 saw stable overall results with 4% organic product sales growth and strong order rates, offset by a 26% service revenue decline, mainly in EMEA. Guidance for FY26 is maintained, with margin improvement expected in the second half and continued investments in innovation and commercial expansion.
Fiscal Year 2025
-
Record revenue and robust margins were achieved despite industrial sector headwinds, with strong growth in APAC and e-commerce, successful DTA integration, and significant capital returns. Fiscal 2026 guidance anticipates continued growth, margin expansion, and active M&A and buyback strategies.
-
Record Q3 revenue with 6% year-over-year growth, strong performance in Americas and Cortland Biomedical, and robust DTA orders. Gross margin declined due to service mix and tariffs, but pricing actions and restructuring support profitability. Guidance maintained, with cautious outlook amid economic and geopolitical uncertainty.
-
Organic sales grew 5% year-over-year, with strong performance in HLT and robust growth in Americas and APAC. EBITDA margins declined due to mix, but guidance and cash flow targets are maintained, supported by a strong balance sheet and ongoing innovation.
-
Revenue grew 2.3% year-over-year, driven by EMEA, Asia-Pacific, and Cortland Biomedical, while the Americas lagged due to weak industrial demand. Gross margin and EBITDA margin declined, but adjusted EPS rose 3% and free cash flow improved. Integration of DTA and ongoing operational initiatives support future growth.
Fiscal Year 2024
-
Fiscal 2024 saw modest organic growth, margin expansion, and strong free cash flow, despite a soft industrial market. The DTA acquisition broadens capabilities and geographic reach, while 2025 guidance anticipates continued margin strength and disciplined capital allocation.
-
Margin expansion and operational efficiency gains drove improved profitability despite a soft industrial market. EMEA delivered strong double-digit growth, while APAC faced headwinds. Innovation, e-commerce, and disciplined capital allocation supported positive outlook.